Insulin therapy for type 2 diabetes.
Open accessThe DOI matches its Crossref record; 64 of the 66 references it cites were found in a registry or an index.
Abstract
A number of landmark randomized clinical trials established that insulin therapy reduces microvascular complications (1,2). In addition, recent follow-up data from the U.K. Prospective Diabetes Study (UKPDS) suggest that early insulin treatment also lowers macrovascular risk in type 2 diabetes (3). Whereas there is consensus on the need for insulin, controversy exists on how to initiate and intensify insulin therapy. The options for the practical implementation of insulin therapy are many. In this presentation, we will give an overview of the evidence on the various insulin regimens commonly used to treat type 2 diabetes. Secondary analyses of the aforementioned landmark trials endeavored to establish a glycemic threshold value below which no complications would occur. The UKPDS found no evidence for such a threshold for A1C, but instead showed that better glycemic control was associated with reduced risks of complications over the whole glycemic range (“the lower the better”) (4). For the management of type 2 diabetes, this resulted in the recommendation to “maintain glycemic levels as close to the nondiabetic range as possible” (5). However, in contrast to the UKPDS, the Kumamoto study observed a threshold, with no exacerbation of microvascular complications in patients with type 2 diabetes whose A1C was <6.5%, suggesting no additional benefit in lowering A1C below this level (2). Moreover, the intensive glycemia treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, targeting A1C <6.0%, was discontinued because of higher mortality in this group compared with the standard therapy group targeting A1C from 7.0 to 7.9% (6). Therefore, the American Diabetes Association (ADA) recommendation of an A1C target <7.0% seems the most balanced compromise at present (7). Another important conclusion of the UKPDS was that the risk reductions in long-term complications were related to the levels of glycemic control …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Relationships between mean end point daily insulin dose (A) and the frequency of patient contact (clinical visits and telephone contacts combined) (B) and mean reduction in A1C, and between mean end point daily insulin dose and mean weight gain (C), during nine randomized trials investigating insulin initiation with NPH insulin, insulin detemir, or insulin glargine. Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C). B does not include Holman, since this publication did not specify the number of interim telephone contacts. Two trials (28,35) did not report mean end point daily insulin dose as units per kilogram per day. We calculated the desired figures from the mean end point dose reported as units per day and mean body weight at study end. Three studies (Riddle and the two studies of Yki-Järvinen [27,36,37]) did not report reduction in A1C. We calculated these values from mean baseline and end point A1C levels.](https://figures.cochat.ai/paper-figures/1e9a45de404c4ea4814181c7adb4b0e3/insulin-therapy-for-type-2-diabetes-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although increasing the basal insulin dose often improves glycemic control, it can also be associated with increased risk of hypoglycemia and weight gain, resulting in inadequate intensification of insulin dose in clinical practice.1”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C).”
Cited by
Items 101–180 of 180
Recent Progress Toward More Sustainable Biomanufacturing
Hearn, M. T. W. (2017) · Wiley eBooks · doi:10.1002/9781119031116.ch18 · Cited by 8
Boye, K. S., Poon, J. L., Landó, L. F., Sapin, H., Huh, R., Wang, M., WILLIAMSON, S. E., & Patel, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01620-8 · Cited by 8
MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses
Niu, F., Liu, M., Yovanovich, C., Vigersky, R. A., Shin, J. J., & MCVEAN, J. J. F. (2026) · Diabetes Care · doi:10.2337/dc25-2124 · Cited by 7
Kiconco, R., Lumumba, S. A., Bagenda, C. N., Atwine, R., Ndarubweine, J., & Rugera, S. P. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241232280 · Cited by 10
Oral insulin delivery – challenges and strategies
Sonia, T. A., & Sharma, C. P. (2014) · Elsevier eBooks · doi:10.1533/9781908818683.113 · Cited by 8
Bi, Y., Li, X., Yang, D., Hao, Y., Liang, H., Zhu, D., & Weng, J. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00187.x · Cited by 8
Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System
Heade, J., McCartney, F., Chenlo, M., Marro, O. M., Severic, M., Kent, R. M., Bleiel, S. B., Álvarez, C. V., Griffin, B. T., & Brayden, D. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050656 · Cited by 7
Gonzalez-Flo, E., Kheirabadi, E., Rodríguez‐Caso, C., & Macía, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1149698 · Cited by 6
Long-term air pollution exposures on type 2 diabetes prevalence and medication use
Meng, Y., Yu, Y., Babey, S. H., & Su, J. G. (2023) · Hygiene and Environmental Health Advances · doi:10.1016/j.heha.2023.100062 · Cited by 9
Kim, S. S., Kim, I. J., Kim, Y. K., Yoon, K., Son, H., Park, S. W., Sung, Y., Baek, H. S., & Ha, K. S. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0572-4 · Cited by 7
Perriello, G., Caputo, S., Pergola, G. D., Carlo, A. D., Grassi, G., Lapolla, A., Pata, P., Solerte, S. B., & Zaccardi, F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.626766 · Cited by 6
A ten-year study of anti-diabetic drugs utilization in Iran
Yousefi, N., Hemmati, F., Jaddi, Z. S., & Salamzadeh, J. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-00983-8 · Cited by 6
Yarlagadda, C., Abutineh, M., Reddy, A. J., Landau, A. B., Travis, L. M., Perrone, C. G., Idriss, A., & Patel, R. P. (2023) · Cureus · doi:10.7759/cureus.36438 · Cited by 7
“Insulin therapy is the current gold standard of glycemic control in patients with uncontrolled diabetes and is indicated to begin if maximally dosed dual oral therapy is unsuccessful [23].”
BackgroundTeens' concerns: a national evaluation.
Boehm, K. E., Schondel, C., Marlowe, A. L., & Manke-Mitchell, L. (1999) · PubMed · Cited by 12
Busch, R. S., Ruggles, J., Han, J., & Hardy, E. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.13029 · Cited by 6
Neuhauser, C., Schwarzinger, B., Schwarzinger, C., Feichtinger, M., Stadlbauer, V., Arnaut, V., Drotarova, I., Blank‐Landeshammer, B., & Weghuber, J. (2024) · Nutrients · doi:10.3390/nu16142182 · Cited by 6
Pollock, R. F., Curtis, B. H., Smith‐Palmer, J., & Valentine, W. J. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0065-1 · Cited by 5
Song, K., Kim, J. M., Noh, J.-H., Park, Y., Son, H.-S., Min, K. W., & Ko, K. S. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.2.117 · Cited by 5
Baltzis, D., Grammatikopoulou, M. G., Παπάνας, Ν., Trakatelli, C., Kintiraki, E., Hassapidou, M. N., & Manes, C. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0300-2 · Cited by 5
Diabetes-inducing effects of bronchial asthma
Al‐Beltagi, M., Bediwy, A. S., Saeed, N. K., Bediwy, H. A., & Elbeltagi, R. M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.97954 · Cited by 4
Yuan, C. Y., Halim, B., Kong, Y. W., Lu, J., Dutt‐Ballerstadt, R., Eckenberg, P., Hillen, K., Koski, A., Milenkowic, V., Netzer, E., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241236771 · Cited by 4
Lingvay, I., Catarig, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Evans, L. M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01344-7 · Cited by 3
The future of diabetes mellitus management: Therapeutic insights from gene and stem cell research
Das, S. S., Vignesh Balaji, E., & Pai, K. S. R. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102292 · Cited by 3
Ansari, M., Prajapati, K. P., Mittal, S., Bhati, V., Gupta, V., Mishra, S., Patidar, S., Mahato, O. P., Bhandari, A. K., Anand, B. G., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00286 · Cited by 3
Caporale, J., Pichón-Rivière, A., Beratarrechea, A. G., Schulz-Hausmann, C. V., & Augustovski, F. (2014) · Value in Health Regional Issues · doi:10.1016/j.vhri.2014.02.007 · Cited by 3
Designing a ‘Ready-to-Use’ powder formulation platform for the inhaled protein therapeutics
Lee, S. H., Yap, W. X., Jiang, C. Q. Z., Ler, W. X., Teo, J. W. P., Ng, S. K., & Heng, D. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103820 · Cited by 3
Functional improvement in β cell models of type 2 diabetes using on-demand feedback control
Koyama, K., Ando, H., & Fujiwara, K. (2023) · AIP Advances · doi:10.1063/5.0124625 · Cited by 4
Røder, M. E. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1043270 · Cited by 3
Intensifying Treatment of Type 2 Diabetes Mellitus: Adding Insulin
Peters, K. R. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.54s · Cited by 4
Hassanein, M., Dahi, W. A., Radhi, H. T., AIMahfouz, A., Kaabi, J. A., Alshammari, A. M., Al-Futaisi, A., Almalki, M., & Malik, R. A. (2022) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000521437 · Cited by 2
PKPD Modeling and Simulations to Support Biosimilar Development of Biphasic Insulin Aspart 30
Petrov, A. V., Zinnatulina, B. R., Васильевич, Д. Р., Каронова, Т. Л., Koksharova, E., Dorotenko, A. R., & Макаренко, И. Е. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1152 · Cited by 2
Wang, X., Plantinga, A., Xiong, X., CROMER, S. J., Bonzel, C.-L., Panickan, V. A., Duan, R., Hou, J., & Cai, T. (2024) · JMIR Diabetes · doi:10.2196/58137 · Cited by 3
Subbaiah, M. V., Babu, K. L. P., Manohar, D., Sumalatha, A., Mohammed, P., & Mahitha, B. (2021) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v11i1-s.4749 · Cited by 2
Post-graduate medical education in the time of COVID-19: Not a remotely simple task
Romeo, G. R., Shaikh, Y. A., & Middelbeek, R. J. W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.980505 · Cited by 3
“We applaud new programs established within the American Rescue Plan Act (ARPA) (21) that fund broadband infrastructure projects andprovidefinancial assistance for Internet costs to eligible households; yet, in the short term inequalities in distribution of high-speed connectivity in rural areas and among minorities an…”
MethodAkhtar, S., Wangnoo, S., Ghosal, S., Shetty, R., & Tripathi, S. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.139239 · Cited by 2
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
Latif, Z. A., Pathan, M. F., Siddiqui, M. N. I., Sobhan, M. J., Rahman, M. M., & Ashrafuzzaman, S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(13)70007-x · Cited by 2
Proinsulin C-peptide-mediated signalling and the search for its receptor
Janabi, A. M. (2017) · Figshare · doi:10.13140/rg.2.2.30079.30888 · Cited by 5
Nakitto, B., Opedo, M., Nansubuga, F., Omondi, E., Musinguzi, E., Otile, E. C., Ekak, S., Nannungi, C., Apiyo, P., Pebolo, P. F., et al. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241247650 · Cited by 1
Alghadeer, S. M., Mubarak, A. M., Alsuwayni, B. M., Al-Murdhi, F. M., Al-Malki, H. S., & Alotaibi, M. S. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102168 · Cited by 1
Rahaman, M. A., Das, A. K., Ray, S., Islam, T., Akther, N., Ansari, M. A. J., Prasad, I., Saifuddin, M., Islam, M., & Sharifuzzaman, M. (2023) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_20_22 · Cited by 1
Gerber, A., & Quinn, R. E. (2023) · Hospital Pharmacy · doi:10.1177/00185787231185868 · Cited by 1
Yeung, C.-K., Fhkam, F., Ngai, W., & Lau, I. T. (2017) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2017.73009 · Cited by 1
Stimuli-responsive polymers for treatment of diabetes mellitus
Patra, S., Madhuri, R., & Sharma, P. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-101995-5.00020-9 · Cited by 3
Beliefs of Caribbean type 2 diabetes patients towards insulin therapy and prescription
Ezenwaka, C. E., Onuoha, P. C., Extavour, R. M., & Yearwood, S. S. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00808-5 · Cited by 1
Understanding the Interplay between COVID-19 and Diabetes Mellitus
Mohammedsaeed, W. M., Ahmedi, S., & Manzoor, N. (2020) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2020.812001 · Cited by 1
Romeo, G. R., Silva, P. S., & Cavallerano, J. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_294 · Cited by 1
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac116.1417314184 · Cited by 1
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
New therapies for diabetes mellitus
Barbieri, M., Cataldo, V., Griffing, G. T., & Paolisso, G. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch87 · Cited by 1
Patient-adjusted versus health professional-adjusted insulin dosing for type 2 diabetes mellitus
Ng, C. J., Liew, S. M., Vethakkan, S. R., Abdullah, A. B., & Teng, C. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010574
RetractedGordon-Dseagu, V. (2014) · UCL Discovery (University College London)
Cox, C. (2015) · Digital Commons - Winthrop University (Winthrop University)
Transition to Insulin in Patients with Type-2 Diabetes
Ebner, S. A., & Miller, J. D. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_43
Peyrot, M. F., Barnett, A. H., & Meneghini, L. F. (2012)
Pedro-González, E. A., Huerta-Ramírez, S., Cerda-Téllez, E. F., Geuguer-Chávez, E. L., & López-Véjar, A. C. E. (2014) · Medicina Interna de México
Kıraç, C. O., İpekçi, S. H., Baldane, S., Tezcan, H., & Kebapçılar, L. (2020) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.686649
Romeo, G. R., Silva, P. S., & Cavallerano, J. D. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_294-1
The current state of diabetes treatment
Danquah, M. K., & Jeevanandam, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85396-5.00007-5 · Cited by 2
Advanced drug delivery system in the treatment of hyperglycemia and hypoglycemia
Arora, V., Kabra, A., Sharma, R. B., Dureja, H., & Dua, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00019-0
Management of Type 2 Diabetes With Insulin Glargine-100 in Iraq in a Real-Life Observation
Mansour, A. A., Rahmah, A. M., & Khudhair, M. (2022) · Cureus · doi:10.7759/cureus.31164 · Cited by 3
“Although insulin is not required by all patients with T2DM, it might be indispensable to achieve good glycemic control [13], due to a progressive decline in beta-cell function or to the failure of oral anti-diabetes drugs (OADs) [14].”
BackgroundNegash, Z., & Mekonen, T. (2023) · Metabolism Open · doi:10.1016/j.metop.2022.100228
“1% in the rural setting of Northwest Ethiopia have been reported [5].”
BackgroundWati, H., Astuti, K. I., Ramadhani, S., Kurniawan, G., Rahmadina, A., & Wahyunita, S. (2023) · Jurnal Ilmiah Farmasi (Scientific Journal of Pharmacy) · doi:10.20885/jif.specialissue2023.art5 · Cited by 3
Type 2 Diabetes at a Military Health Centre in Brazil: Clinical and Pharmacotherapeutic Profile
Bessa, A. H. F. D. B. E., Ueta, J. M., Mayrink, V. D., & de Oliveira, R. E. M. (2024) · Clinical Diabetology · doi:10.5603/cd.98362
Kshanti, I. A., Magfira, N., Widyastuti, A. A. A., Nasarudin, J., Epriliawati, M., & Mokoagow, M. I. (2024) · doi:10.2196/preprints.65359
Bramian, A., Ling, K., Butsenko, D., Komatsu, D. E., & Wang, E. D. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04173-z
The Impact of Cardiovascular Exercise on Diabetes Management
Pham, P. (2025) · International journal of high school research · doi:10.36838/v7i4.7
Existing pharmacological challenges and the need for improved therapies
Dubey, R., Pandey, S. K., Gajbhiye, T., Pandey, M., Tiwari, A., & Tewari, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00004-x
Opara, C., White, A., Fulda, K. G., Blair, S. E., Aduwari, C., Nukala, N., & Xiao, Y. (2025) · Pharmacy · doi:10.3390/pharmacy13040093
Glycemic Index of the Rice Noodles
Tan, B. L., & Norhaizan, M. E. (2025) · SpringerBriefs in food, health and nutrition · doi:10.1007/978-3-031-98649-9_7
Kshanti, I. A. M., Magfira, N., Widyastuti, A. A. A., Nasarudin, J., Epriliawati, M., & Mokoagow, M. I. (2025) · JMIR Diabetes · doi:10.2196/65359
Development of an Advanced Drug Delivery System for Protein- and Peptide-Based Therapeutics
Lai, W. F., Kee, P. E., Ming, L. C., Chew, Y.-L., Lee, S.-K., Bostanudin, M. F., Uddin, A. B. M. H., & Liew, K. B. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128394343250910234044
Hayati, H., & Zahabi, R. A. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07497-5
Oral insulin delivery—Challenges and strategies
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00012-3
Additional file 1 of Barriers and facilitators to insulin treatment: a phenomenological inquiry
Bayked, E. M., Kahissay, M. H., & Workneh, B. D. (2022) · Figshare · doi:10.6084/m9.figshare.20341737
Passos, P. R. C., Motta, R. V., Filho, V. O. C., Noronha, M. M., Venâncio, R. C., Cançado, G. G. L., Adler, A., Cobbold, J., & Tomlinson, J. (2026) · Diabetes Care · doi:10.2337/dc26-0336 · Cited by 1
Ali, M. Y., Kim, D. H., Jung, H. J., Nam, T., & Choi, J. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156914
“Insulin therapy is beneficial as a treatment of DM, but drawbacks include insulin resistance and development of fatty liver upon prolonged insulin use [3].”
Role of vasular endothelial growth factor (VEGF) in diabetic complication
Kumar, N., Kumar, S., Sharma, R. K., Kumar, B., Sharma, P., Jain, A., Debnath, A., Sharma, P., & Verma, S. (2026) · AIP conference proceedings · doi:10.1063/5.0286245
Metadata
- Authors
- Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Swinnen, Sanne G.
- ORCID
- DeVries, J. Hans
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S253-S259
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2811456
- OpenAlex
- W2131037080
- Semantic Scholar
- a5b8f30bf6ffc652e3e70e51ae28659874032190
- Cited by
- 181
- References
- 66
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 12 · 2020: 14 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Sanofi
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin therapy, type 2 diabetes, insulin regimens, glycemic control, HbA1c targets, microvascular complications, UKPDS, ACCORD trial, tight glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Insulin, Quality of Life, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.